Public procurement notice: Contract Award Notice
Published: 2021-11-22
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33000000 | 38000000
Estimated value: 5200000 NOK
Award criteria: The most economic tender

Technical requirements: Lääketieteelliset laitteet, farmaseuttiset valmisteet ja henkilökohtaiseen hygieniaan liittyvät tuotteet
Reagents for carrying out quantitative PCR tests for the cytomegalovirus (CMV) and Epstein-Barr virus (EBV)
From Voluntary ex-ante transparency notice: Helse Bergen HF intends to enter into a temporary contract with Roche Diagnostics AS for the delivery of reagents for carrying out quantitative CMV and EBV analyses. The contract will be for 1 year with an option for an extension for up to 1 year.
The background for the temporary contract with Roche is that Helse Bergen HF would like to use an instrument that has already been installed in the Laboratory Clinic. The instrument must be fully automatic, and there is only one instrument in the clinic with the correct qualities. At the current time it is not appropriate to invest in new instruments, as there is neither the space or resources available for this. Neither is there a need for other functions that the two analyses. It is therefore expedient to use the existing instrumentation for this. See point II.2.4) for further information.
From Voluntary ex-ante transparency notice: Helse Bergen HF intends to enter into a temporary contract with Roche Diagnostics AS for the delivery of reagents for carrying out quantitative CMV and EBV analyses. The contract will be for 1 year with an option for an extension for up to 1 year.
The background for the temporary contract with Roche is that Helse Bergen HF would like to use an instrument that has already been installed in the Laboratory Clinic. The instrument must be fully automatic, and there is only one instrument in the clinic with the correct qualities. At the current time it is not appropriate to invest in new instruments, as there is neither the space or resources available for this. Neither is there a need for other functions that the two analyses. It is therefore expedient to use the existing instrumentation for this.
The Microbiology Department carries out CMV-PCR and EBV-PCR in plasma by using Cobas Ampliprep/TaqMan 48 (Roche) and MagNA Pure 96/LightCycler 2.0 (Roche) respectively. With the exception of MagNA Pure 96, these are analysis instruments that are no longer manufactured and are being phased out. There is therefore a need to replace the analysis platform for these analyses. As the two analyses are often carried out on the same indication, it is important that they can be carried out on the same analysis platform, and that it is sufficient with one sample tube per patient.
Experience has shown us that quantitative PCR must be carried out on fully automated analysis platforms, where both extraction and PCR is included in the reagent package. A total system consisting of extraction and PCR gives a standardised set-up. This is important for the quality assurance of the analysis products, both as regards measuring uncertainties and the risk of sample mix-ups.
- quick analyses, which can be particularly important in some cases, particularly in organ transplant cases.
- possibility for ØH diagnostics in critically ill patients, as reagents can be stored in the instrument
- standardised analysis set-up with reduced measuring uncertainty as the extraction and PCR are on the same platform.
Based on the named justifications, the contracting authority believes that there is a legal basis to enter into a contract with Roche Diagnostics AS without a call for tenders, cf. Public Procurement Regulations Section 21-5, c.f. section13-4 first paragraph, letter b, point 2.
Helse Bergen HF intends to enter into a temporary contract with Roche Diagnostics AS for the delivery of reagents for carrying out quantitative CMV and EBV analyses. The contract will be for 1 year with an option for an extension for up to 1 year. The background for the temporary contract with Roche is that Helse Bergen HF would like to use an instrument that has already been installed in the Laboratory Clinic. The instrument must be fully automatic, and there is only one instrument in the clinic with the correct qualities. At the current time it is not appropriate to invest in new instruments, as there is neither the space or resources available for this. Neither is there a need for other functions that the two analyses. It is therefore expedient to use the existing instrumentation for this. The justification for using a fully automatic solution: The Microbiology Department carries out CMV-PCR and EBV-PCR in plasma by using Cobas Ampliprep/TaqMan 48 (Roche) and MagNA Pure 96/LightCycler 2.0 (Roche) respectively. With the exception of MagNA Pure 96, these are analysis instruments that are no longer manufactured and are being phased out. There is therefore a need to replace the analysis platform for these analyses. As the two analyses are often carried out on the same indication, it is important that they can be carried out on the same analysis platform, and that it is sufficient with one sample tube per patient. Experience has shown us that quantitative PCR must be carried out on fully automated analysis platforms, where both extraction and PCR is included in the reagent package. A total system consisting of extraction and PCR gives a standardised set-up. This is important for the quality assurance of the analysis products, both as regards measuring uncertainties and the risk of sample mix-ups. Such a fully automatic solution ensures: - quick analysis response, which can be particularly important in certain circumstances, particularly in connection with organ transplants, the possibility to carry out both CMV- and EBV-PCR in one and the same test - traceability from sample to result - possibility for ØH diagnostics for critically ill patients, where reagents can be stored on the instrument. - little manual pipetting with the loading it entails - reduced risk for sample mix-up/contamination during the analysis process - standardised analysis set-up with reduced measurement uncertainty due to an extraction and PCR is part of the same platform. Based on named justifications, the contracting authority believes there is legal basis to enter into a contract with Roche Diagnostics AS without announcing a contest.
Reagents for carrying out quantitative PCR tests for the cytomegalovirus (CMV) and Epstein-Barr virus (EBV)


Winner: Roche Diagnostics Norge AS
Award value: 5200000
Number of bids: 1